There's not enough scientific evidence to determine whether omega-3 fatty acid supplements can help treat people with bipolar disorder, say researchers at the University of Oxford in England.
People with bipolar disorder can shift between mania (elevated mood and energy) and depression. However, the use of omega-3 supplements to treat bipolar disorder is worthy of further study, since they seem to have no serious side effects, and many experts recommend them for people with heart disease and some immune disorders, said study authors Paul Montgomery and Alex Richardson.
They reviewed five studies that examined the use of omega-3 supplements for bipolar disorder, but only one study of 75 patients had enough data on results for Montgomery and Richardson to analyze.
Patients in that study had less severe depression symptoms while taking the supplements, but there was no change in their mania symptoms.
To read more of this content at the Washington Post, click here.
Showing posts with label animal supplements. Show all posts
Showing posts with label animal supplements. Show all posts
Saturday, April 26, 2008
Wednesday, March 26, 2008
Press Release: CV Technologies Set for Growth Says CEO
EDMONTON, ALBERTA--(Marketwire - March 26, 2008) - CV Technologies Inc. (TSX:CVQ) - CV Technologies' recent financial and operational performance sets the stage for successful long-term growth through product line and geographic diversification, said President, CEO and Chief Scientific Officer Dr. Jacqueline Shan, speaking today to the Company's Annual General Meeting of shareholders at the Alberta Research Council in Edmonton.
"Our road map is predicated on our belief that CV Technologies will continue as a leader in our product category in Canada, and that we will extend the COLD-fX® line and introduce other new products," Dr. Shan said. She observed that "Canada will remain our engine, serving as a showcase for our products and generating the financial and other resources that we expect will ultimately permit us to thrive in the global market".
"Our initial investment of money and time in establishing U.S. relationships continues to demonstrate benefits. We have maintained favorable profiles with respected U.S. opinion leaders in the scientific, regulatory, medical and journalistic communities. And we are confident their goodwill will translate into support for future efforts, when the time is right," she said.
"Recently, the U.S. Food and Drug Administration approved the first botanical drug product. We are exploring the possibility of obtaining U.S. botanical drug registration for COLD-fX, which would allow us to make therapeutic claims," Dr. Shan remarked. "In addition, we are in early stage discussions with potential strategic partners about the prospects for developing new products and extensions to our existing lines for global distribution. We are also exploring licensing our intellectual property for use in industries like functional foods and animal supplements."
To read more of this press release from MarketWire, click here.
"Our road map is predicated on our belief that CV Technologies will continue as a leader in our product category in Canada, and that we will extend the COLD-fX® line and introduce other new products," Dr. Shan said. She observed that "Canada will remain our engine, serving as a showcase for our products and generating the financial and other resources that we expect will ultimately permit us to thrive in the global market".
"Our initial investment of money and time in establishing U.S. relationships continues to demonstrate benefits. We have maintained favorable profiles with respected U.S. opinion leaders in the scientific, regulatory, medical and journalistic communities. And we are confident their goodwill will translate into support for future efforts, when the time is right," she said.
"Recently, the U.S. Food and Drug Administration approved the first botanical drug product. We are exploring the possibility of obtaining U.S. botanical drug registration for COLD-fX, which would allow us to make therapeutic claims," Dr. Shan remarked. "In addition, we are in early stage discussions with potential strategic partners about the prospects for developing new products and extensions to our existing lines for global distribution. We are also exploring licensing our intellectual property for use in industries like functional foods and animal supplements."
To read more of this press release from MarketWire, click here.
Subscribe to:
Posts (Atom)
